Navigation Links
Resverlogix Phase 1b/2a Study Meets Primary Endpoint
Date:8/25/2009

e including Drs. Nissen, Nicholls, Ballantyne, Taylor, and Kastelein for a Phase 2 study in cardiovascular disease patients which will be discussed in conjunction with the 2009 European Society of Cardiology Congress meeting in Barcelona, Spain. Resverlogix will be attending this important cardiovascular meeting and will communicate the results of the 28 day study to potential partners in greater detail, under confidentiality agreement. Furthermore, Dr. Norman Wong will present RVX-208 data on September 2, 2009 for Resverlogix during this meeting.

Since RVX-208 increases ApoA-I by production the Phase 1b/2a trial also examined early markers for ApoA-I production and reverse cholesterol transport such as pre-beta-HDL and Alpha1-HDL. Approximately half of the subjects had low levels of HDL cholesterol, a condition associated with significant increased risk of cardiovascular disease.

"Showing in the Phase 1b/2a trial that we met the primary endpoint of increasing plasma ApoA-I in a safe and tolerable way is a huge milestone for Resverlogix," stated Donald J. McCaffrey, President CEO of Resverlogix. "There is an enormous unmet medical need in treating atherosclerosis and cardiovascular disease and the ApoA-I increases achieved by RVX-208 may just do that. We expect to update shareholders with further details of these activities later this year," added McCaffrey.

In addition to successfully completing the Phase 1b/2a trial, Resverlogix has also completed two arms of a Phase 1 BE (bio-equivalency) study for RVX-208 with the final arm being scheduled for completion in the end of the third quarter. The Phase 1 BE trial is a program designed to show that the newly formed capsule version of RVX-208 is equivalent to the earlier powder in a bottle version that has been used in all trials to date.

In unrelated news Mr. Kelly McNeill, Resverlogix CFO, will be leaving his current position effective September 18, 2009 and returning to Winnipeg for
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
2. Resverlogix Provides Quarterly Update
3. Resverlogix Board of Directors Update
4. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
5. Resverlogix Announces Closing of Debt Redemption
6. Resverlogix Eliminates Sixty Percent of Remaining Debt
7. Resverlogix Issues a Management Statement
8. Resverlogix Board of Directors Update
9. Resverlogix Notice of Conference Call & Webcast
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogixs Lead Drug Featured in Key Scientific Publication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ELLYN, Ill. , July 2, 2015 ... Colton Eakins are gaining invaluable real-world experiences ... of Technology this summer. The students will ... Dr. Jeff Wereszczynski,s research group at IIT. The ... Dr. Tom Carter , Physics; Dr. Kathy ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, ... largest provider of surgical instruments to the Spine Industry. The acquisition of Turner ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The next-generation ... several key market segments, including the molecular diagnostics industry. BCC Research reveals in its ... of NGS-based tests, lower test costs, and a growing need for better diagnostics as ...
(Date:7/1/2015)... Ariz. , July 1, 2015 Isagenix ... it has earned three Gold, three Silver, and three ... Awards gala held in Chicago ... as the premier business awards program in the U.S. ... recognizes our company,s strength in developing leaders, cultivating talent, ...
Breaking Biology Technology:COD Students Participate in Prestigious Summer Internships 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... ... EDMONTON, May 9 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS),a leading ... on its pipeline products, HYC750 and development with,BioCyDex Inc., The ... Inc. for HYC750, a technology based on hyaluronic acid that,has a ...
... Hungary, May 9 Genetic,Immunity, a US/Hungarian clinical-stage ... for targeted immune amplification, announced,today that the Company ... 5th,Annual Global Healthcare Conference to be held May ... in Monte Carlo, Monaco. The Company,s President,and Chief ...
... Celator Pharmaceuticals today,announced that Scott Jackson has been ... October 2007 as Head of Commercial,Development., "We ... CEO. He brings more than 20,years of pharmaceutical ... in oncology," said Dr. Joseph Mollica,Chairman of Celator,s ...
Cached Biology Technology:BioMS Medical Provides Update On Pipeline Products 2BioMS Medical Provides Update On Pipeline Products 3Genetic Immunity To Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO 2
(Date:6/16/2015)... GOTHENBURG, Sweden , June 16, 2015 ... including all touch fingerprint sensors in the company,s portfolio from ... . Deliveries are planned to mainly take place during the ... manufacturers in Asia . Jörgen ... another evidence of    the   growing interest from smartphone ...
(Date:6/15/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... announces that its leading payment security technology, the Wocket® smart ... NYC June 18th. Digital Experience! @ NYC is ... to over 300 of the top media covering the sector. ... New York City from 6:00 to ...
(Date:6/9/2015)... MINNETONKA, Minn. , June 9, 2015   ... that supports the entire spectrum of clinical research, will ... eClinical technology platform at the 2015 Drug Information ... on June 15-17.  These presentations will include ... be rolled out in the upcoming iMedNet ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... the idea has become predominant that the best way ... for it in the framework of markets. The great ... a glimpse of many possibilities for money-earning uses of ... Convention on Biological Diversity, a measure adopted in Rio ...
... colonies? To Kenya to count monkeys? To Tasmania to track ... in North America? No worries, theres a field guide ... and wacky but mostly practical field guides to ... purposeful knots and English churchyard lichens. Diane Schmidt, the ...
... than 99 percent of all modern potato varieties planted ... grew in the lowlands of south-central Chile. How Chilean ... from Europe-has been the subject of a long, contentious ... have maintained that Chilean potatoes were the first to ...
Cached Biology News:Markets of biodiversity and equity in trade: An illusion? 2Markets of biodiversity and equity in trade: An illusion? 3U. of I. librarian launches comprehensive Web database of field guides 2U. of I. librarian launches comprehensive Web database of field guides 3Using DNA, scientists hunt for the roots of the modern potato 2
...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... cell labeling mix, 92.5 MBq, ... stabilized with 0.1% 2-mercaptoethanol and ... acid. *Amino acid mixture for ... l-[35S]Methionine and l-[35S]Cysteine. * > ...
...
Biology Products: